Regression of hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2745-2747

  Takahashi, Ken ^a   Nishida, Naoshi ^a   Kawabata, Hiroshi ^a   Haga, Hironori ^b   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Hodgkin lymphoma; Interferon

Indexed keywords

CD20 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEIN BCL 6; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPHADENOPATHY; LYMPHOMA; MALE; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; REMISSION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HODGKIN DISEASE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REMISSION INDUCTION; RIBAVIRIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84867802123     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.8404     Document Type: Article

References (9)

1. Chisari FV. Unscrambling hepatitis C virus-host interactions. Na-ture 436: 930-932, 2005.
2. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 55: 634-641, 2012.
3. Zhao FX. Nodular Lymphocyte-predominant Hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: The problem in "Grey Zone" lymphomas. Int J Clin Exp Pathol 1: 300-305, 2008.
4. Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 17: 184-189, 2007.
5. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347: 89-94, 2002.
6. Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 145: 255-257, 2009.
7. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leuke-mia 18: 1711-1716, 2004.
8. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, di-agnosis, and management. Oncologist 11: 384-392, 2006.
9. Jonasch E, Haluska FG. Interferon in oncological practice: a re-view of Interferon biology, clinical applications and toxicities. On-cologist 6: 34-55, 2001.